DK3562821T3 - Isoquinolinforbindelser, fremgangsmåder til fremstilling af disse og terapeutiske anvendelser af disse ved tilstande associeret med ændringen i aktiviteten af beta-galactosidase - Google Patents
Isoquinolinforbindelser, fremgangsmåder til fremstilling af disse og terapeutiske anvendelser af disse ved tilstande associeret med ændringen i aktiviteten af beta-galactosidase Download PDFInfo
- Publication number
- DK3562821T3 DK3562821T3 DK17829043.3T DK17829043T DK3562821T3 DK 3562821 T3 DK3562821 T3 DK 3562821T3 DK 17829043 T DK17829043 T DK 17829043T DK 3562821 T3 DK3562821 T3 DK 3562821T3
- Authority
- DK
- Denmark
- Prior art keywords
- galactosidase
- beta
- activity
- preparation
- methods
- Prior art date
Links
- 102000005936 beta-Galactosidase Human genes 0.000 title 1
- 108010005774 beta-Galactosidase Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382660 | 2016-12-28 | ||
| PCT/IB2017/058438 WO2018122746A1 (en) | 2016-12-28 | 2017-12-27 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3562821T3 true DK3562821T3 (da) | 2021-02-15 |
Family
ID=57777485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17829043.3T DK3562821T3 (da) | 2016-12-28 | 2017-12-27 | Isoquinolinforbindelser, fremgangsmåder til fremstilling af disse og terapeutiske anvendelser af disse ved tilstande associeret med ændringen i aktiviteten af beta-galactosidase |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023042177A1 (en) | 2021-09-20 | 2023-03-23 | Gt Gain Therapeutics Sa | Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide |
| CN122122139A (zh) * | 2023-11-02 | 2026-05-29 | Gt增益治疗股份有限公司 | 取代的吲哚基化合物、其组合物及其治疗用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526560D0 (en) | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
| DE19740785A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Arylsulfonamide und Analoga |
| HRP20010795A2 (en) | 1999-04-28 | 2003-02-28 | Aventis Pharma Gmbh | Di-aryl acid derivatives as ppar receptor ligands |
| WO2001058899A1 (en) | 2000-02-09 | 2001-08-16 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| EP1433776B1 (en) | 2001-09-07 | 2011-01-19 | Seikagaku Corporation | Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient |
| JP2006519258A (ja) | 2003-02-28 | 2006-08-24 | エンサイシブ・ファーマシューティカルズ・インコーポレイテッド | ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ii受容体拮抗薬 |
| US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| PE20050952A1 (es) * | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| WO2005070929A1 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP2007526324A (ja) | 2004-03-02 | 2007-09-13 | スミスクライン・ビーチャム・コーポレイション | Akt活性のある阻害剤 |
| CA2555914A1 (en) | 2004-03-08 | 2005-09-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
| WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| WO2006058201A2 (en) * | 2004-11-23 | 2006-06-01 | Reddy Us Therapeutics, Inc. | Heterocyclic and bicyclic compounds, compositions and methods |
| BRPI0516915A (pt) | 2004-12-01 | 2008-03-11 | Devgen Nv | derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv |
| AU2006204750C1 (en) | 2005-01-14 | 2012-11-01 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| AT502145B1 (de) | 2005-03-24 | 2012-01-15 | Univ Graz Tech | Glycosidase-hemmendes iminoalditol |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| ATE508126T1 (de) | 2005-11-16 | 2011-05-15 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| JP2010500330A (ja) | 2006-08-10 | 2010-01-07 | フエルレル インターナショナル,ソシエダッド アノニマ | Gabaa受容体に対して親和性を有する1h−キノリン−4−オン化合物、方法、使用及び組成物 |
| EP1903034A1 (en) | 2006-09-19 | 2008-03-26 | Technische Universität Graz | Iminosugar glycoconjugates |
| WO2009042294A2 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| WO2009049422A1 (en) | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease |
| CN102743385B (zh) * | 2007-11-16 | 2014-09-17 | 沃泰克斯药物股份有限公司 | Atp结合盒转运蛋白的异喹啉调节剂 |
| ES2337435B8 (es) | 2008-10-22 | 2011-07-19 | Consejo Superior De Investigaciones Cientificas (Csic) (25%) | Compuestos potenciadores de la actividad de glicosidasas mutantes. |
| RU2505539C2 (ru) | 2008-12-23 | 2014-01-27 | Эбботт Лэборетриз | Антивирусные соединения |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| WO2011049737A1 (en) | 2009-10-19 | 2011-04-28 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating lysosomal storage disorders |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| LT2685986T (lt) | 2011-03-18 | 2020-03-10 | Genzyme Corporation | Gliukozilceramido sintazės slopiklis |
| WO2013005168A2 (en) * | 2011-07-05 | 2013-01-10 | Lupin Limited | Cannabinoid receptor modulators |
| SG11201402765TA (en) * | 2011-12-30 | 2014-06-27 | Hanmi Pharm Ind Co Ltd | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
| CA2883386A1 (en) * | 2012-09-14 | 2014-03-20 | Eternity Bioscience Inc. | Aminoisoquinoline derivatives as protein kinase inhibitors |
| BR122021012629B1 (pt) | 2013-02-01 | 2022-06-07 | Wellstat Therapeutics Corporation | Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos |
| EP3027590A1 (en) * | 2013-07-31 | 2016-06-08 | Minoryx Therapeutics S.L. | Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof |
| AU2014347027A1 (en) | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | GSK -3 inhibitors |
| US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
| JP6239149B2 (ja) | 2014-04-25 | 2017-11-29 | ファイザー・インク | 複素芳香族化合物およびそのドーパミンd1リガンドとしての使用 |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| WO2016120808A1 (en) * | 2015-01-28 | 2016-08-04 | Minoryx Therapeutics S.L. | Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof |
-
2017
- 2017-12-27 WO PCT/IB2017/058438 patent/WO2018122746A1/en not_active Ceased
- 2017-12-27 BR BR112019013593-6A patent/BR112019013593A2/pt not_active IP Right Cessation
- 2017-12-27 CN CN201780086786.5A patent/CN110494432B/zh not_active Expired - Fee Related
- 2017-12-27 ES ES17829043T patent/ES2862374T3/es active Active
- 2017-12-27 EP EP17829043.3A patent/EP3562821B9/en active Active
- 2017-12-27 CA CA3047700A patent/CA3047700A1/en active Pending
- 2017-12-27 AU AU2017388300A patent/AU2017388300B2/en not_active Ceased
- 2017-12-27 PL PL17829043T patent/PL3562821T3/pl unknown
- 2017-12-27 DK DK17829043.3T patent/DK3562821T3/da active
- 2017-12-27 JP JP2019535381A patent/JP7144863B2/ja active Active
- 2017-12-27 PT PT178290433T patent/PT3562821T/pt unknown
- 2017-12-27 US US16/473,966 patent/US11440898B2/en active Active
-
2019
- 2019-06-20 IL IL267553A patent/IL267553B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017388300A1 (en) | 2019-07-11 |
| AU2017388300B2 (en) | 2022-03-31 |
| CA3047700A1 (en) | 2018-07-05 |
| JP7144863B2 (ja) | 2022-09-30 |
| IL267553B (en) | 2021-10-31 |
| ES2862374T3 (es) | 2021-10-07 |
| CN110494432A (zh) | 2019-11-22 |
| IL267553A (en) | 2019-08-29 |
| EP3562821B9 (en) | 2021-05-26 |
| JP2020514284A (ja) | 2020-05-21 |
| PL3562821T3 (pl) | 2021-06-14 |
| WO2018122746A1 (en) | 2018-07-05 |
| US20200071294A1 (en) | 2020-03-05 |
| EP3562821A1 (en) | 2019-11-06 |
| CN110494432B (zh) | 2022-08-12 |
| EP3562821B1 (en) | 2020-12-02 |
| BR112019013593A2 (pt) | 2020-01-07 |
| PT3562821T (pt) | 2021-03-03 |
| US11440898B2 (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259534A (en) | Structures for microfluidic isolation are produced at the place of assembly, kits and their uses | |
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| IL257486A (en) | Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder | |
| DK3253865T3 (da) | Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller | |
| DK3207130T3 (da) | Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme | |
| DK3185854T3 (da) | Injicerbare opslæmninger og fremgangsmåder til fremstilling og anvendelse af disse | |
| DK3303317T3 (da) | Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3377484T3 (da) | Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet | |
| DK2951754T3 (da) | Fremgangsmåder, systemer og software til identifikation af biomolekyler med interagerende komponenter | |
| DK3024497T3 (da) | Fremgangsmåder og præparater til behandling af hjernesygdomme | |
| DK2935303T3 (da) | 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK2968418T3 (da) | Præparater afledt af placentamaterialer til fremstilling og anvendelse deraf | |
| EP3680332C0 (en) | SAMPLE PREPARATION SYSTEM AND CARTRIDGE | |
| IL247458A0 (en) | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| DK2815769T3 (da) | Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet | |
| DK3395354T3 (da) | Plasminogen til anvendelse i behandling af diabetisk nefropati | |
| DK3467904T3 (da) | Separator med høj vådbarhed og fremgangsmåde til fremstilling deraf | |
| DK3386523T3 (da) | Bifidobacterium longum til behandling af fedme og associerede metabolske sygdomme | |
| DK3348557T3 (da) | Imidazo[1,2-a]pyridiner til behandling eller forebyggelse af hyperurekæmi eller gigt | |
| DK3247352T3 (da) | Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion |